Lupus Nephritis Clinical Trials in Dallas, Texas

5 studies are recruiting for lupus nephritis in Dallas, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. A Phase 2, Open-Label, Single-Arm Trial of FT819 in Participants With Lupus Nephritis

   The primary objective of this trial is to evaluate the efficacy and safety of FT819, comprised of allogeneic T cells that express a CD19-targeted CAR, following bendamustine administration in participants with refractory moderate-to-severe lupus nephritis, as assessed by the proportion of participa…

   Stage

   Phase 2

   Ages

   12 to 70

   Site

   The University of Texas Southwestern Medical Center, Dallas, Texas

   Locations

   12 in total

   Run by

   Fate Therapeutics

   See if you can join NCT07570862 on ClinicalTrials.gov

2. PRESERVE: LUPKYNIS in Combination With Belimumab, Obinutuzumab or Anifrolumab in Patients With Lupus Nephritis

   The goal of this clinical study is to assess the efficacy and safety of LUPKYNIS® in combination with belimumab, obinutuzumab or anifrolumab at inducing rapid renal response in patients with lupus nephritis (LN).

   Stage

   Phase 4

   Ages

   18 to 75

   Site

   Liberty Research Center, Dallas, Texas

   Locations

   27 in total

   Run by

   Aurinia Pharmaceuticals Inc.

   See if you can join NCT07611214 on ClinicalTrials.gov

3. Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V

   The overall purpose of this two-part study is to evaluate the efficacy, safety and tolerability of iptacopan (LNP023) in addition to standard of care treatment.

   Stage

   Phase 2

   Ages

   18 to 100

   Site

   Dallas Nephrology Associates, Dallas, Texas

   Locations

   103 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT05268289 on ClinicalTrials.gov

4. A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)

   This is a Phase 1/2, open-label, multi-center, multi-cohort, non-randomized dose escalation and dose expansion basket study to determine the safety and tolerability of NKX019 (allogeneic CAR NK cells targeting CD19) in participants with autoimmune diseases.

   Stage

   Phase 1

   Ages

   18 to 75

   Site

   Nkarta Investigational Site, Dallas, Texas

   Locations

   19 in total

   Run by

   Nkarta, Inc.

   See if you can join NCT06557265 on ClinicalTrials.gov

5. Lupus Landmark Study: A Prospective Registry and Biorepository

   The purpose of the registry and biorepository is to provide a mechanism to store clinical data, linked biospecimens and molecular data to support the conduct of future research on Systemic Lupus Erythematosus (SLE), including Lupus Nephritis (LN).

   Stage

   Not phased

   Ages

   18 to 110

   Site

   UT Southwestern Medical Center, Dallas, Texas

   Locations

   25 in total

   Run by

   Lupus Research Alliance

   See if you can join NCT05934149 on ClinicalTrials.gov